BiotechTube

Slow release oral morphine (SROM) + Methadone

Phase 3Terminated
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Opioid-Related Disorders

Conditions

Opioid-Related Disorders, Opiate Substitution Treatment, Morphine, Methadone, Fentanyl

Trial Timeline

Dec 6, 2019 → Jun 1, 2020

NCT ID
NCT03948464

About Slow release oral morphine (SROM) + Methadone

Slow release oral morphine (SROM) + Methadone is a phase 3 stage product being developed by Mayne Pharma Group for Opioid-Related Disorders. The current trial status is terminated. This product is registered under clinical trial identifier NCT03948464. Target conditions include Opioid-Related Disorders, Opiate Substitution Treatment, Morphine.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03948464Phase 3Terminated

Competing Products

2 competing products in Opioid-Related Disorders

See all competitors
ProductCompanyStageHype Score
Naltrexone for extended-release injectable suspension + Oral naltrexoneAlkermesApproved
82
NaltrexoneAlkermesApproved
82

Other Products from Mayne Pharma Group

Sporanox + LozanocApproved
77
Halobetasol Topical FoamApproved
77
Doxycycline Hyclate Delayed-Release 200 mgApproved
77
Permethrin Cream, 5% + ElimitePhase 3
69
Ivermectin 0.5% Topical Application Lotion + Ivermectin 0.5% Topical Application Lotion [SKLICE] + Placebo 0% LotionPhase 3
69